SEPN Key Statistics, Chart & Performance
The current stock price of SEPN is 26.17 USD. In the past month the price increased by 30.52%. In the past year, price increased by 1.63%.
SEPN Latest News, Press Relases and Analysis
SEPN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About SEPN
Company Profile
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 75 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. The company is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Company Info
SEPTERNA INC
250 East Grand Avenue, Suite 65
South San Francisco CALIFORNIA US
Employees: 75
Phone: 16503383533
SEPTERNA INC / SEPN FAQ
What does SEPN do?
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. The company is headquartered in South San Francisco, California and currently employs 75 full-time employees. The company went IPO on 2024-10-25. The firm is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. The company is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. The company is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
What is the stock price of SEPTERNA INC today?
The current stock price of SEPN is 26.17 USD. The price decreased by -5.25% in the last trading session.
Does SEPN stock pay dividends?
SEPN does not pay a dividend.
How is the ChartMill rating for SEPTERNA INC?
SEPN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists SEPN stock?
SEPN stock is listed on the Nasdaq exchange.
How is the valuation of SEPTERNA INC (SEPN) based on its PE ratio?
SEPTERNA INC (SEPN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).
What is SEPTERNA INC worth?
SEPTERNA INC (SEPN) has a market capitalization of 1.17B USD. This makes SEPN a Small Cap stock.
SEPN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SEPN. When comparing the yearly performance of all stocks, SEPN is one of the better performing stocks in the market, outperforming 92.6% of all stocks.
SEPN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SEPN. No worries on liquidiy or solvency for SEPN as it has an excellent financial health rating, but there are worries on the profitability.
SEPN Financial Highlights
Over the last trailing twelve months SEPN reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -53868.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.88% | ||
| ROE | -14% | ||
| Debt/Equity | 0 |
SEPN Forecast & Estimates
11 analysts have analysed SEPN and the average price target is 28.22 USD. This implies a price increase of 7.83% is expected in the next year compared to the current price of 26.17.
For the next year, analysts expect an EPS growth of 100.45% and a revenue growth 10618.3% for SEPN